Geroscience – Salutary effects of transdermal curcumin on multiple indices of health span in rodent models of normal aging and lifespan (2025) Read the full article
PNAS Nexus – Targeting sickle cell pathobiology with novel transdermal curcumin (2025) Read the full article
Scientific Reports – Biopreservation and reversal of oxidative injury during blood storage by a novel curcumin-based gel formulation (2024) Read the full article
66th ASH – Mechanism Based Treatable Targets for Organ Damage and Pain in SCD (2024) Read the full article
Einstein Magazine – Harnessing an Ancient Remedy (Winter-Spring 2023) Read the full article
Artificial Cells, Nanomedicine, and Biotechnology – Novel Transdermal Curcumin Therapeutic Preserves Endothelial Barrier Function in a High Dose LPS Rat Model (2022) Read the full article
Vascarta has partnered with the City University of New York (CUNY) to enhance chemotherapy effectiveness and safety through a novel linker chemistry platform. This collaboration aims to reduce side effects and improve outcomes in cancer care using curcumin-linked therapeutic compounds. Read the full article
Vascarta’s VAS-101 has demonstrated improved preservation of stored red blood cells, extending their lifespan in circulation. Ex vivo and in vivo studies conducted at the FDA and UC San Diego highlight its potential to enhance transfusion efficacy and patient outcomes. Read the full article
At the ASH Conference in San Diego, Vascarta presented encouraging results on its transdermal curcumin gel. The data suggests potential therapeutic benefits for individuals with sickle cell disease, offering a new approach to managing symptoms through improved bioavailability and ease of use. Read the full article
Vascarta unveiled its highly bioavailable transdermal curcumin gel at the American Society of Hematology Conference. The innovation may provide a safe, effective, and non-invasive option for treating sickle cell disease, with promising implications for patient care. Read the full article